Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterol...
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
About this item
Full title
Author / Creator
Cheng, Samuel M. S. , Mok, Chris Ka Pun , Leung, Yonna W. Y. , Ng, Susanna S. , Chan, Karl C. K. , Ko, Fanny W. , Chen, Chunke , Yiu, Karen , Lam, Bosco H. S. , Lau, Eric H. Y. , Chan, Ken K. P. , Luk, Leo L. H. , Li, John K. C. , Tsang, Leo C. H. , Poon, Leo L. M. , Hui, David S. C. and Peiris, Malik
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in the serum of convalescent or vaccinated individuals to understand potential loss of protection against infection by Omicron. We previously established that a 50% plaque reduction neutrali...
Alternative Titles
Full title
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2622285437
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2622285437
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-022-01704-7
